Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04098081 · ClinicalTrials.gov registry record · Phase 2
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Advanced Pancreatic Cancer, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04098081 is a Phase 2 study of Advanced Pancreatic Cancer that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 15 participants, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04098081, a Phase 2 study of Advanced Pancreatic Cancer, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG galeterone
Study Locations (1)
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04098081
The ClinicalTrials.gov registry entry for NCT04098081 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (80% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT04098081 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04098081 about?
NCT04098081 is a clinical study titled "1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma". Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma
What is the current status of trial NCT04098081?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-12-12. Estimated completion is 2027-12-31.
What conditions does trial NCT04098081 study?
This clinical trial studies the following conditions: Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT04098081?
The interventions under investigation include: Gemcitabine (DRUG), galeterone (DRUG).
Who is sponsoring clinical trial NCT04098081?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04098081 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 2
-
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.